Department of Veterans Affairs April 16, 2018 – Federal Register Recent Federal Regulation Documents
Results 1 - 2 of 2
Notice of Intent To Grant an Exclusive License
Notice is hereby given that the Department of Veterans Affairs (VA), Office of Research and Development, Technology Transfer Program, intends to grant to Meiogen Biotechnology Corporation, 20 Assembly Square Drive, Somerville, MA 02145, an exclusive license to U.S. patent application No. 62/571,900 (``Compositions and Methods of Interferon Alpha Binding Proteins'') VA Invention Disclosure number 2018-010 titled, ``B18R (NormferonTM-alpha).'' The invention provides compositions comprising of interferon-alpha binding protein (B18R) and combined anti-retroviral therapy (cART) to treat HIV associated neurogenerative disorder (HAND). Ultimately, this invention provides a novel therapeutic option for subjects with HAND.
Revise and Streamline VA Acquisition Regulation To Adhere to Federal Acquisition Regulation Principles (VAAR Case 2014-V001)
The Department of Veterans Affairs (VA) in this final rule amends six clauses or provisions and removes one clause which duplicates current FAR coverage and is not needed, provides updated policy on variations, tolerances and exemptions regarding overtime in contracts providing nursing home care for veterans, removes an information collection burden on an outdated practice of using bid envelopes; clarifies language regarding the prohibition of contractors from making reference in their commercial advertising, and revises definitions relating to D&S Committee, Debarring Official and Suspending Official currently contained in the VAAR. This document adopts as a final rule, with three technical non-substantive changes, the proposed rule published in the Federal Register on May 17, 2017.
This site is protected by reCAPTCHA and the Google
Privacy Policy and
Terms of Service apply.
